GlassScriptPhysician profile
Frank G Simon
NPI 1336147065
$1,899.29
in general payments reported to CMS, 2019-2025
18 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
See the full distribution for Allergy & Immunology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $110 · 2021: $204 · 2022: $259 · 2023: $322 · 2024: $488 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $946.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $945.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $434.59 | 2019-2023 | Nucala |
| Phathom Pharmaceuticals, INC. | $369.43 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $326.80 | 2019-2023 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $193.26 | 2020-2024 | Fasenra, Airsupra |
| Genzyme Corporation | $131.34 | 2022-2024 | |
| Optinose US, INC. | $99.66 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $83.04 | 2020-2021 | |
| Allergan, INC. | $48.02 | 2020 | |
| Upsher-Smith Laboratories LLC | $44.41 | 2021 | |
| Genentech USA, INC. | $25.41 | 2022 | |
| Abbvie INC. | $25.40 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $24.26 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.24 | 2024 | Cuvitru |
| Circassia INC. | $18.80 | 2019 | |
| Impel Pharmaceuticals INC. | $15.96 | 2023 | Trudhesa |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $15.53 | 2025 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $12.39 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.